Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5HX8

Jak1 complex with 4-[(4-aminocyclohexyl)amino]-3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one

Summary for 5HX8
Entry DOI10.2210/pdb5hx8/pdb
DescriptorTyrosine-protein kinase JAK1, 4-[(4-aminocyclohexyl)amino]-3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one (3 entities in total)
Functional Keywordskinase, inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationEndomembrane system; Peripheral membrane protein: P23458
Total number of polymer chains2
Total formula weight70139.97
Authors
Su, H.P. (deposition date: 2016-01-29, release date: 2016-03-16, Last modification date: 2024-10-23)
Primary citationSimov, V.,Deshmukh, S.V.,Dinsmore, C.J.,Elwood, F.,Fernandez, R.B.,Garcia, Y.,Gibeau, C.,Gunaydin, H.,Jung, J.,Katz, J.D.,Kraybill, B.,Lapointe, B.,Patel, S.B.,Siu, T.,Su, H.,Young, J.R.
Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
Bioorg.Med.Chem.Lett., 26:1803-1808, 2016
Cited by
PubMed Abstract: The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, non-receptor tyrosine kinases whose activities have been associated in the literature and the clinic with a variety of hyperproliferative diseases and immunological disorders. At the onset of the program, it was hypothesized that a JAK1 selective compound over JAK2 could lead to an improved therapeutic index relative to marketed non-selective JAK inhibitors by avoiding the clinical AEs, such as anemia, presumably associated with JAK2 inhibition. During the course of the JAK1 program, a number of diverse chemical scaffolds were identified from both uHTS campaigns and de novo scaffold design. As part of this effort, a (benz)imidazole scaffold evolved via a scaffold-hopping exercise from a mature chemical series. Concurrent crystallography-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.
PubMed: 26927423
DOI: 10.1016/j.bmcl.2016.02.035
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.2 Å)
Structure validation

226707

PDB entries from 2024-10-30

PDB statisticsPDBj update infoContact PDBjnumon